Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Clinical trial NCT04843943 · UNKNOWN

Trial details

NCT number: NCT04843943
Sponsor: Fudan University
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2021-05-01
Primary completion: 2022-05-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.